What are the new readings
New evidence is the term that medical providers use to indicate that a procedure or drug was judged to be appropriate or necessary. New indications refer to new applications of an existing prevention, diagnosis or treatment of the disease. This is a positive report to provide accurate specialists based on established testing methodologies. The next step is usually clinical trials before officially approved by the regulating Association in the country.
Breaking new evidence
New indications are often used in news releases on medical treatments and pharmaceutical companies when referring to their drugs or equipment. For example, on April 16, 2018, the FDA issued a new policy, the approval of the drug Opdivo (nivolumab) for the treatment of melanoma, advanced Non-small cell lung cancer, a common renal cell carcinomas and MSI-H or dMMR metastatic colorectal cancer, classical Hodgkin’s lymphoma, advanced squamous cell carcinoma of the head and neck, urothelial carcinoma and hepatocellular carcinoma. Compare this to his first claim in December 2014, which was limited to treatment for patients with melanoma that could not be removable with surgery or who no longer responded to other medications.
New evidence should not be approved by the FDA for introduction and use among health care workers. In 2017, the scientist ran a story about the industry that has emerged around re-purposing existing drugs for new indications. The story Features how the organization treats the Director-General Bruce bloom within reach, a company that funded 10 projects reshaping of the drugs that were looking for new indications for existing (or failed) products. Forty percent of these projects, recommendations were made which empowered physicians to resurrect drugs to deliver off-label treatment of patients. There are large costs associated with repeatedly moving the drug into phase 2 and phase 3 trials for FDA approval, but many companies prefer to incur these costs; investments in the earlier approvals for the drug was done, and less risk, these drugs are already widely studied in the preclinical development.
The relevance of new evidence to investors
Investors owning shares of pharmaceutical companies should take note of any major new indications not announced for their drugs. New indications for drugs can lead to a potentially higher demand for the drug due to the projected additional use on top of the previous. It can also indicate underlying company potentially higher share prices. Thus, large pharmaceutical companies such as Pfizer, offer dedicated news sections investor on their websites, with press releases that cover FDA approval for new indications for their drugs.